Crebankitug - Zura Bio
Alternative Names: ZB-168Latest Information Update: 28 Jul 2025
At a glance
- Originator Pfizer
- Developer Pfizer; Zura Bio
- Class Antihyperglycaemics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 7 receptor alpha subunit inhibitors; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Ulcerative colitis
- Phase I Multiple sclerosis
- Preclinical Alopecia areata; Immunological disorders
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in United Kingdom (Parenteral)
- 09 May 2024 Phase-II clinical trials in Atopic dermatitis (Parenteral), before May 2024
- 09 May 2024 Phase-II clinical trials in Ulcerative colitis (Parenteral), before May 2024